Journal article
Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial
- Abstract:
-
Eosinophilic airway inflammation is often present in asthma, and reduction of such inflammation results in improved clinical outcomes. We hypothesised that fevipiprant (QAW039), an antagonist of prostaglandin D2 receptor 2, might reduce eosinophilic airway inflammation in patients with moderate-to-severe eosinophilic asthma.We performed a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial at Glenfield Hospital (Leicester, UK). We recruited patients with persiste...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Accepted manuscript, pdf, 877.3KB)
-
- Publisher copy:
- 10.1016/S2213-2600(16)30179-5
Authors
Funding
National Institute for Health Research
More from this funder
AirPROM
More from this funder
Novartis Pharmaceuticals
More from this funder
Bibliographic Details
- Publisher:
- Elsevier Publisher's website
- Journal:
- Lancet Respiratory Medicine Journal website
- Volume:
- 4
- Issue:
- 9
- Pages:
- 699-707
- Publication date:
- 2016-09-01
- DOI:
- EISSN:
-
2213-2619
- ISSN:
-
2213-2600
- Pmid:
-
27503237
- Source identifiers:
-
638767
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:638767
- UUID:
-
uuid:f07c58de-6462-4d8d-92c4-6960249f2623
- Local pid:
- pubs:638767
- Deposit date:
- 2016-09-21
Terms of use
- Copyright holder:
- Elsevier Ltd
- Copyright date:
- 2016
- Notes:
- Copyright © 2016 Elsevier Ltd. This is the accepted manuscript version of the article. The final version is available online from Elsevier at: https://doi.org/10.1016/S2213-2600(16)30179-5
If you are the owner of this record, you can report an update to it here: Report update to this record